Sameer Kalghatgi, Ph.D., a former postdoctoral fellow in Collins laboratory who is now Senior Plasma Scientist at EP Technologies in Akron, Ohio, and Catherine S
CANTATA: primary analysis of a global, randomized, placebo (Pbo)-controlled, double-blind trial of telaglenastat (CB-839)+ cabozantinib versus Pbo+ cabozantinib in advanced/metastatic renal cell carcinoma (mRCC) patients (pts) who progressed on immune checkpoint inhibitor (ICI) or anti-angiogenic therapies
But some will notice side effects, minor or annoying, yet not dangerous
Markku Lhteenvuo, a psychiatric researcher at Niuvanniemi Hospital in Finland, said: I see so many patients who do not have good outcomes on the medications we have and who are desperate for help with their addiction
Pyrrolidine dithiocarbamate alleviated anxiety in diabetic mice
doi: 10.1080/15513815.2019.1666330